Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q2 2020 · 10-Q
Revenue$115.93M$115.93M+33.7% vs Q2 2019 Net Income$1.66M$1.66MN/M vs Q2 2019 EPS Diluted$0.02$0.02N/M vs Q2 2019 Gross Profit$90,451,000+37.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$12,741,000+40.5% Free Cash Flowderived$9,426,000+41.3% Margins · derivedGross margin78.0%+2.4 pt vs Q2 2019
Operating margin5.8%+4.4 pt vs Q2 2019
Net margin1.4%+2.9 pt vs Q2 2019
ended Jun 30, 2020 · filed Jul 30, 2020 · 30 d after period end